Abstract 247P
Background
Evaluate Role of ADC values in assessing response to chemoradiotherapy in cervix cancer & contribution of contrast MRI to identify residual disease, post-treatment completion.
Methods
Prospective observational study in 100 patients of histopathologically proven cancer of the uterine cervix. Based on clinical outcome integrating final histopathological diagnosis patients were classified as either complete response or Residual disease. Validity & reliability of PET-CT, Contrast MRI, and ADC values were checked by calculating sensitivity, specificity, PPV & NPV.
Results
Residual lesions have significantly lower ADC value than that of post-treatment changes. Mean ADC values of residual tumors: 1.26±0.238 x 10-3 mm2/s and mean ADC values of lesions due to post-treatment changes: 1.540 ±0.218 x 10-3 mm2/s (statistically significant difference in between malignant and post-treatment lesions p < 0.05). ADC sensitivity 67%, specificity 83%, PPV 35%, NPV 95 % and accuracy 81% in differentiating residual disease from post-treatment changes. PPV, NPV, sensitivity, and specificity with PET-CT was 93%, 89%, 98%, and 73%. PPV, NPV, sensitivity, and specificity of contrast MRI was 16%, 91%, 58%, and 59%.
Conclusions
Diffusion imaging differentiates residual cervix malignancies from post-treatment changes based on ADC values and can be a promising and evocative biomarker. Complimentary use of ADC and PET/CT may increase diagnostic confidence. However, the cost and logistics of MRI imaging is an important factor in routine clinical implementation especially in developing countries like India, where carcinoma cervix is associated with poor socioeconomic status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract